The U.S. Food and Drug Administration has proposed removing oral phenylephrine, widely used in cold and cough syrups, as an active ingredient ... ingredient Companies such as Procter & Gamble and GSK ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

GSK has taken another step towards rebuilding ... in late-stage development as a chronic cough therapy. The big pharma needs to boost its pipeline as it is facing patent expiry in 2027 for HIV ...

Therapeutic area expertise motivated GSK to acquire Bellus Health and develop a new medicine for patients with refractory chronic cough ... agreements with Hansoh Pharma for novel ADCs in oncology.

New Delhi: At least 6% cough syrup samples belonging to 54 Indian pharmaceutical manufacturers failed the mandatory quality test for export till October this year, according to government data.

Japan’s Taisho Pharmaceutical ... and over-the-counter medicine manufacturer – the largest in Japan and known for brands like Lipovitan energy drinks and Pabron cough/cold range – reckons ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Less of the rapid pneumonia breathing; less of the fever, the sucking chest, the rattling cough, the blue lips ... the greatest achievements of modern medicine. Measles, for example, was killing ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Millions of adolescents in Africa could be living unknowingly with asthma as cases go undiagnosed, researchers find.